Skip to main content

Table 1 Baseline characteristics

From: Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study

Variable

All patients

(n = 524) %

POD24 group

(n = 143) %

Non-POD24 group

(n = 381) %

p-value

Median age, range (yrs)

63 (18–98)

66 (19–98)

62 (18–93)

0.003

Sex, n (%)

   

0.57

 Males

268 (51)

76 (53)

192 (50)

 

 Females

256 (49)

67 (47)

189 (50)

 

BMI ≤ 30 kg/m2, n (%)

340 (69)

94 (72)

246 (68)

0.34

MZL subtype, n (%)

   

0.04

 NMZL

124 (24)

45 (32)

79 (21)

 

 SMZL

135 (26)

33 (23)

102 (27)

 

 EMZL

265 (50)

65 (45)

200 (52)

 

ECOG PS, n (%)

   

0.03

 0–1

448 (91)

111 (85)

337 (93)

 

  ≥ 2

46 (9)

19 (15)

27 (7)

 

Stage, n (%)

   

0.21

 1–2

140 (27)

31 (22)

109 (29)

 

 3–4

376 (73)

110 (78)

266 (71)

 

B symptoms, n (%)

106 (21)

35 (25)

71 (19)

0.12

LDH > ULN, n (%)

135 (27)

46 (36)

89 (24)

0.01

Albumin < ULN, n (%)

80 (16)

29 (22)

51 (14)

0.03

B2M > ULN, n (%)

129 (52)

35 (53)

94 (52)

0.88

Monoclonal protein, n (%)

151 (32)

62 (47)

89 (27)

 < 0.0001

BM involvement, n (%)

243 (55)

69 (57)

174 (55)

0.59

Median WBC, K/uL (range)

6.2 (0.7–131)

5.8 (0.7–54.2)

6.3 (1.6 – 131)

0.21

Median Hgb, g/dL (range)

12.5 (3.7–18.9)

12.3 (5.5–15.6)

12.6 (3.7–18.9)

0.20

First-line treatment, n (%)

   

0.02

 Rituximab alone

296 (56)

95 (66)

201 (53)

 

 R-chemotherapy

200 (38)

42 (29)

158 (41)

 

 Others

28 (5)

6 (4)

22 (6)

 
  1. BMI body mass index, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, ULN upper limit of normal, B2M beta 2 microglobulin, BM bone marrow